Solid tumors resulting from oncogenic stimulation of neurotrophin receptors (TRK) by chimeric proteins are a group of rare tumors of various localization that respond to therapy with targeted drugs entrectinib and larotrectinib. The standard method for detecting chimeric TRK genes in tumor samples today is considered to be next generation sequencing with the determination of the prime structure of the chimeric transcripts. We hypothesized that expression of the chimeric tyrosine kinase proteins in tumors can determine the specific transcriptomic profile of tumor cells. We detected differentially expressed genes allowing distinguishing between TRK-dependent tumors papillary thyroid cancer (TC) from other molecular variants of tumors of this type. Using PCR with reverse transcription (RT-PCR), we identified 7 samples of papillary TC carrying a EVT6-NTRK3 rearrangement (7/215, 3.26%). Using machine learning and the data extracted from TCGA, we developed of a recognition function for predicting the presence of rearrangement in NTRK genes based on the expression of 10 key genes: AUTS2, DTNA, ERBB4, HDAC1, IGF1, KDR, NTRK1, PASK, PPP2R5B, and PRSS1. The recognition function was used to analyze the expression data of the above genes in 7 TRK-dependent and 10 TRK-independent thyroid tumors obtained by RT-PCR. On the test samples from TCGA, the sensitivity was 72.7%, the specificity — 99.6%. On our independent validation samples tested by RT-PCR, sensitivity was 100%, specificity — 70%. We proposed an mRNA profile of ten genes that can classify TC in relation to the presence of driver NTRK-chimeric TRK genes with acceptable sensitivity and specificity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann. Oncol. 2019;30(Suppl 8):viii5-viii15. https://doi.org/10.1093/annonc/mdz383
Arora C, Kaur D, Naorem LD, Raghava GPS. Prognostic biomarkers for predicting papillary thyroid carcinoma patients at high risk using nine genes of apoptotic pathway. PLoS One. 2021;16(11):e0259534. https://doi.org/10.1371/journal.pone.0259534
Asa SL, Giordano TJ, LiVolsi VA. Implications of the TCGA genomic characterization of papillary thyroid carcinoma for thyroid pathology: does follicular variant papillary thyroid carcinoma exist? Thyroid. 2015;25(1):1-2. https://doi.org/10.1089/thy.2014.0540
Bastos AU, de Jesus AC, Cerutti JM. ETV6-NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult population. Eur. J. Endocrinol. 2018;178(1):83-91. https://doi.org/10.1530/EJE-17-0499
Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731-747. https://doi.org/10.1038/s41571-018-0113-0
Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod. Pathol. 2019;32(1):147-153. https://doi.org/10.1038/s41379-018-0118-3
Hsiao SJ, Zehir A, Sireci AN, Aisner DL. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. J. Mol. Diagn. 2019;21(4):553-571. https://doi.org/10.1016/j.jmoldx.2019.03.008
Kel A, Boyarskikh U, Stegmaier P, Leskov LS, Sokolov AV, Yevshin I, Mandrik N, Stelmashenko D, Koschmann J, Kel-Margoulis O, Krull M, Martínez-Cardús A, Moran S, Esteller M, Kolpakov F, Filipenko M, Wingender E. Walking pathways with positive feedback loops reveal DNA methylation biomarkers of colorectal cancer. BMC Bioinformatics. 2019;20(Suppl 4):119. https://doi.org/10.1186/s12859-019-2687-7
Li Q, Li H, Zhang L, Zhang C, Yan W, Wang C. Identification of novel long non-coding RNA biomarkers for prognosis prediction of papillary thyroid cancer. Oncotarget. 2017;8(28):46136-46144. https://doi.org/10.18632/oncotarget.17556
Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M. Oncogenes in solid human tumours. Nature. 1982;300:539-542. https://doi.org/10.1038/300539a0
Saftencu M, Braicu C, Cojocneanu R, Buse M, Irimie A, Piciu D, Berindan-Neagoe I. Gene Expression Patterns Unveil New Insights in Papillary Thyroid Cancer. Medicina (Kaunas). 2019;55(8):500. https://doi.org/10.3390/medicina55080500
Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Identifying patients with NTRK fusion cancer. Ann. Oncol. 2019 Nov 1;30(Suppl_8):viii16-viii22. https://doi.org/10.1093/annonc/mdz384
Supplitt S, Karpinski P, Sasiadek M, Laczmanska I. Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine. Int. J. Mol. Sci. 2021;22(3):1422. https://doi.org/10.3390/ijms22031422
Yang X, Hu Y, Shi H, Zhang C, Wang Z, Liu X, Chen H, Zhang L, Cui D. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma. Eur. Arch. Otorhinolaryngol. 2018;275(8):2127-2134. https://doi.org/10.1007/s00405-018-5045-x
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 173, No. 2, pp. 231-236, February, 2022
Rights and permissions
About this article
Cite this article
Kechin, A.A., Ivanov, A.A., Kel, A.E. et al. Prediction of EVT6-NTRK3-Dependent Papillary Thyroid Cancer Using Minor Expression Profile. Bull Exp Biol Med 173, 252–256 (2022). https://doi.org/10.1007/s10517-022-05528-w
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-022-05528-w